Revolution Medicines (RVMD) - Uzoq muddatli qarzning kapitalga nisbati
Dori vositalarini ishlab chiqishning gumanitar holati tufayli Revolution Medicines (RVMD) geosiyosatdan qat'i nazar, barqaror faoliyat yuritmoqda. Kompaniyaga tegishli daromadlar oshqozon-ichak va o'pka o'smalarini davolash uchun innovatsion dori vositalarini bozorga olib chiqishga asoslangan. Bozor tendentsiyasi 0.47 ko'rsatkichini namoyish etmoqda, moliyaviy muvaffaqiyat esa murakkab mutatsiyalar uchun noyob terapiya usullariga bo'lgan davlat jamg'armalari va klinikalar talabiga bog'liq.
%20Uzoq%20muddatli%20qarzning%20o'z%20kapitaliga%20nisbati&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_RVMD_-_Revolution-Medicines_-_Long-Term-Debt-to-Equity "revmed.com (RVMD): Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi 04.07.2022dan 31.10.2026gacha | 👁️GURU.Markets👁️")
Revolution Medicines kompaniyasining tahliliy kesimlari
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- kompaniyaning balans qiymati tafsilotlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Revolution Medicines|RVMD - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati revmed.com|RVMD - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Revolution Medicines, Inc.|RVMD - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Revolution Medicines|Tezkor likvidlik koeffitsiyenti revmed.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
Kompaniyaning umumiy tahlili:Revolution Medicines Inc - RVMD
Ushbu koeffitsiyent bir yildan ortiq muddatli majburiyatlarning umumiy miqdorini umumiy kapital bilan solishtirish orqali moliyaviy leveraj darajasini belgilaydi. Uzoq muddatli qarzning kapitalga nisbatini tahlil qilish orqali investor Revolution Medicines (RVMD) moliyaviy tuzilmasining barqarorligini baholaydi, bunda qarz mablag'larining muvozanati innovatsion RAS inhibitorlarining qimmatbaho ishlab chiqilishini ta'minlash va kompaniyaning terapevtik ustunligini mustahkamlash uchun hal qiluvchi ahamiyatga ega.
Muhim raqobatchilar
Uzoq muddatli qarzning o'z kapitaliga nisbati BeiGene Ltd. (ONC)|Uzoq muddatli qarzning kapitalga nisbati HALO|Uzoq muddatli qarzning kapitalga nisbati Ascentage Pharma Corp (AAPG)|Uzoq muddatli qarzning o'z kapitaliga nisbati CG Oncology, Inc. CGON|URGN: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Bicara Therapeutics - Uzoq muddatli qarzning kapitalga nisbati|Personalis Inc (PSNL) - Uzoq muddatli qarzning o'z kapitaliga nisbati|ERAS: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Delcath Corp (DCTH)|Uzoq muddatli qarzning o'z kapitaliga nisbati Y-mAbs Therapeutics|AURA: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati SLS (SELLAS Life Sciences Group)|ACTU - Uzoq muddatli qarzning o'z kapitaliga nisbati|CTOR: Uzoq muddatli qarzning o'z kapitaliga nisbati|HURA - Uzoq muddatli qarzning kapitalga nisbati|Protara Therapeutics, Inc. (TARA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Fate Therapeutics Inc - Uzoq muddatli qarzning kapitalga koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati TScan TCRX|Uzoq muddatli qarzning o'z kapitaliga nisbati Champions Oncology (CSBR)|XBIT (xbiotech.com) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati CVM (CEL-SCI)|OS Therapies Inc. (OSTX) - Uzoq muddatli majburiyatlarning kapitalga nisbati|RADX: Uzoq muddatli qarzning o'z kapitaliga nisbati|ARTV: Uzoq muddatli qarzning o'z kapitaliga nisbati|adlainortye.com (ANL) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati verupharma.com (VERU)|Uzoq muddatli qarzning o'z kapitaliga nisbati Tempest Therapeutics, Inc.|Uzoq muddatli qarzning o'z kapitaliga nisbati XLO|Uzoq muddatli qarzning o'z kapitaliga nisbati RENB (Renovaro Inc.)|Uzoq muddatli qarzning kapitalga nisbati muraloncology.com (MURA)|Kairos Pharma - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli kreditlarning kapitalga nisbati OKUR (OnKure Therapeutics, Inc.)|CytoMed - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning kapitalga nisbati Curis, Inc. CRIS|apollomicsinc.com (APLM) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Tharimmune Corporation (THAR)|Uzoq muddatli qarzning o'z kapitaliga nisbati Advanced Biomed Inc.|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi GNPX (genprex.com)|Uzoq muddatli qarzning o'z kapitaliga nisbati CLDI (Calidi Biotherapeutics)|SBFM (Sunshine Biopharma Inc.) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati Xenetic Biosciences, Inc. XBIO|SLRX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Purple Biotech - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati American Oncology Network|BGNE: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi CKPT|ELEV (Elevation Oncology, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|iCAD Corp (ICAD) - Uzoq muddatli qarzdorlikning kapitalga nisbati|Uzoq muddatli qarzning kapitalga nisbati IKNA|Uzoq muddatli qarzning o'z kapitaliga nisbati notablelabs.com NTBL|Uzoq muddatli qarzning kapitalga nisbati VIRX (Viracta Therapeutics, Inc.)|Uzoq muddatli qarzdorlikning kapitalga nisbati MorphoSys Inc (MOR)|NAYA - Uzoq muddatli qarzning o'z kapitaliga nisbati|AAPGV (Ascentage) - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi